 Home > Active Ingredient News > Study of Nervous System > Positive results from phase III trial of long-acting C5 complement inhibitor Ultomiris in neuromyelitis optica

Positive results from phase III trial of long-acting C5 complement inhibitor Ultomiris in neuromyelitis optica

 Last Update: 2022-08-12
 Source: Internet
 Author: User

Tags

central nervous system depressants

anti drug antibodies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system in which the immune system attacks the optic nerve and spinal cord, causing vision loss and paralys.

immunity

AstraZeneca recently reported that Ultomiris (ravulizumab-cwvz) met the primary endpoint of a Phase III study (CHAMPION-NMOSD trial) testing a long-acting C5 complement inhibitor in patients with neuromyelitis optica spectrum disorder (NMOSD) Ultomir.

The study (CHAMPION-NMOSD trial) tested the long-acting C5 complement inhibitor Ultomiris in patients with neuromyelitis optica spectrum disorder (NMOS.

During a median treatment period of 73 weeks, all patients received a single loading dose of Ultomiris on day one, followed by regular maintenance dosing every eight weeks beginning two weeks lat.

CHAMPION-NMOSD data will be presented at an upcoming medical meeting and submitted to global health authorities for approval of this indicati.

child

Original source:

https://firstwordphar.

https://firstwordphar.
com/story/5565669 https://firstwordphar.
com/story/5565669Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Pregabalin (CNS)

CAS No.: 148553-50-8

Pharmacy Grade

$1/KG FOB

Primidone CAS125-33-7

CAS No.: 125-33-7

Pharmaceutical Grade

$100/KG EXW

API Clomipramine HCl

CAS No.: 17321-77-6

Pharmacy Grade

$40-50/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.